

Venture Capital

Spain is one of the countries in Europe with the highest number of start-ups, thanks to its excellence in scientific research, a good entrepreneurial spirit and the excellent environment provided by one of the best healthcare systems in the world.

Few companies manage to develop properly due to the lack of funding, a weakness shared with other European countries. However, the Spanish biotech landscape has completely changed in the last 5 years, with a 138% in private investment and a greater presence of international investors and pharma companies.

Companies such as Ona Therapeutics, Sanifit, Mynorix and others have been able to close high profile financing rounds for European standards, providing visibility and success stories to international investors.

Once Spain has been able to position itself as a country with leading biotech industry, what are the next steps to get to the next level? What are the prospects of already successful companies and how they approach their next financing rounds? How can Spain take advantage, even more, of the dynamism of the international biotech investors? Will the covid-19 pandemic, and the high profile of health biotechnology, help generate new local investment initiatives?

These and more questions will be discussed in this panel.

Moderator:

- **Alberto Sanz**, Director of Financing & Investor Relations, Invest in Spain (Spain)

Speakers:

- **Raúl Martín**, Partner, Ysios Capital Partners (Spain)
- **Hakan Goker**, VicePresident, M-Ventures (Netherlands)
- **Philippe Monteyne**, Partner, Fund+ (Belgium)
- **Valerie Vanhooren**, Co-Founder & CEO, Ona Therapeutics (Spain)